Bruno Villoutreix PhD in Structural Bioinformatics - Drug Design

Course and current status

From Sept 2012 to Sept 2015: Co-director doctoral school: Medicinal Chemistry, Toxicity, Environment (MTCE, presently MTCi)

Since Jan 2009: Founder and director of Inserm-Univ Paris Diderot UMRS-973, Molécules Thérapeutiques in silico (~30 people, in silico Drug discovery, chemoinformatics, Bioinformatics and applications in several therapeutic areas)

2002-2008: head of the Inserm Avenir team (Bioinformatics, Chemoinformatics, Blood coagulation & Complement)

2005: Research Director Inserm, Univ Paris Descartes (Chemistry, Head Prof C. Garbay)

2001: Research Director Inserm, U428, Univ Paris Descartes (Blood coagulation, Head Prof M. Aiach)

1998-2001: Associate Professor, Malmo University Hospital, Sweden (Head Prof B. Dahlback, Blood Coagulation).

1998-2001: Visiting Professor (1 month/year) University of Paris 5, School of Pharmacy.

1996-1997: Visiting scientist Structural Bioinformatics, Malmo University Hospital, Sweden (Blood coagulation & Complement).

1995-1996: Visiting scientist Structural Bioinformatics – Drug Design, VTT Biotechnology, Helsinki, Finland.

1992-1995: Research Assistant Structural Bioinformatics, Scripps Clinic & Research Institute, San Diego, USA (Blood coagulation).

1992: Student training, Electrostatics (3 months) Central Laboratory of Biophysics, Sofia Bulgaria.

1991: Student training, Structural Bioinformatics, Uppsala, Sweden.

1988 and 1990: visiting scientist: enzyme fast kinetics (5 months). Penn State University, USA.

Scientific summary

Protein structure analysis, drug design, virtual screening, ADMET in silico prediction, application of virtual screening and chemical biology mainly to blood coagulation and complement proteins and cancer targets, analysis of patient variations in silico with ongoing work in the area of precision medicine.

I focus on the modulation of challenging therapeutic targets (or mechanism like protein-protein interactions or transient protein-membrane interactions) with low molecular weight compounds and on gaining new insights about molecular mechanisms involved in the health and disease states, the main areas are cancer and blood coagulation while some projects are also on rare diseases and neglected diseases.

Over 200 articles, reviews, meeting abstracts at ISI Web of Science (on Aug 2015), over 10 book chapters and 5 patents and 1 pending

I designed a molecule that is in clinical trial (phase 1b), the study is handled by a start up in Sweden

You can find my directory of weblinks dedicated to in silico methods that assist the early steps of drug discovery here:

This is, to the best of my knowledge, the most complete list of freely available tools and databases on these topics on the "planet"! It is important as it allows to analyze the field and evaluate the strengths, weaknesses, and opportunities

Image d’exemple